Mauna Kea touts data from Cellvizio lung transplant study

This study provides further evidence of the broad potential of the Cellvizio platform to improve diagnostic and treatment outcomes. We thank Dr. Keller and his colleagues for conducting this unique study sponsored by Mauna Kea Technologies and demonstrating that with proper training, the procedure is effective and reproducible. We are optimistic that Cellvizio will increasingly be used in a variety of applications that can benefit from its unique ability to provide real-time diagnostic information at the cellular level. Moreover, image interpretation automation with artificial intelligence will contribute to the performance and adoption of Cellvizio in this and other applications,” CEO & founder Sacha Loiseau said in a press release. Earlier this month, Mauna Kea said it won 510(k) clearance from the FDA for its Confocal miniprobes designed for use with the company’s Cellvizio platform. The Confocal miniprobes are indicated for use in urological and minimally invasive surgical applications along with the near-infared Cellvizio platform. The post Mauna Kea touts data from Cellvizio lung transplant study appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Imaging Mauna Kea Technologies Source Type: news